Intensive Therapy with Autologous Stem Cell Transplantation as First-Line Therapy in Poor-Risk Hodgkin's Disease and Analysis of Predictive Factors of Outcome

References

• Canellos G. P., Anderson J. R., Propert K. J., Nissen N., Cooper M. R., Henderson E. S., Green M. R., Gottlieb A., Peterson B.A. Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med. 1992; 327: 1478–1484
   PubMed Web of Science ®Google Scholar
• Klimo. P., Connors. J. M. An update of the Vancouver experience in the management of advanced Hodgkin's disease treated with the MOPP/ABV hybrid program. Semin Hematol. 1994; 25: 34–40
   Google Scholar
• Hagerneister F. B., Tannir R., McLaughlin P., Salvador P., Riggs S., Velasquez. W. S., Cabanillas. E. MIME chemotherapy (Methyl-GAG, ifosfamide, methotrexate, eto-poside) as treatment for recurrent Hodgkin's disease. J Clin Oncol. 1987; 5: 556–561
   PubMed Web of Science ®Google Scholar
• Longo D. L., Duffey P. L., Young R. C., Hubbard S. M., Ihde D. C., Glatstein E., Phares J. C., Jaffe E. S., Urba. W. J., Devita. V. T. Conventional-dose salvage combination chemotherapy in patients relapsing with Hodgkin's disease after combination chemotherapy: The low probability of cure. J Clin Oncol. 1992; 10: 210–218
   PubMed Web of Science ®Google Scholar
• Armitage J. O., Bierman P. J., Vose J. M., Anderson J. R., Weisenburger D. D., Kessinger A., Reed E. C., Vaughan W. P., Coccia. P. F., Purtilo. D. T. Autologous bone marrow transplantation for patients with relapsed Hodgkin's disease. Am J Med. 1991; 91: 605–611
   PubMed Web of Science ®Google Scholar
• Anderson J. E., Litzow M. R., Appelbaum F. R., Schoch G., Fisher L. D., Buckner C. D., Petersen F. B., Crawford S. W., Press O. W., Sanders J. E., Bensinger W. I., Martin P. J., Storb R., Sullivan K. M., Hansen. J. A., Thomas. E. D. Allogeneic, syngeneic, and autologous marrow transplantation for Hodgkin's disease: The 21-year Seattle experience. J Clin Oncol. 1993; 11: 2342–2350
   PubMed Web of Science ®Google Scholar
• Chopra M., McMillan A. K., Linch D. C., Yukleas S., Taghipour G., Pearce R., Patterson. K. G., Goldstone. A. H. The place of high-dose BEAM therapy and autologous bone marrow transplantation in poor-risk Hodgkin's disease. A single-center eight-year study of 155 patients. Blood 1993; 81: 1137–1145
   PubMed Web of Science ®Google Scholar
• Homing S. J., Chao N. J., Negrin R. S., Hoppe R. T., Long G. D., Hu W. W., Wong R. M., Brown. B. W., Blume. K. G. High-dose therapy and autologous hematopoietic progenitor cell transplantation for recurrent or refractory Hodgkin's disease : Analysis of the Stanford University results and prognostic indices. Blood 1997; 89: 801–813
   PubMed Web of Science ®Google Scholar
• Strauss. D. J. Treatment of advanced Hodgkin's disease. Hematology/Oncology Clinics of North America. 1989; 3: 287–302
   PubMed Web of Science ®Google Scholar
• Carella A. M., Carlier P., Congiu A., Occhini D., Nati S., Santini G., Pierluigi D., Giordano D., Bacigalupo. A., Damasio E. Autologous bone marrow transplantation as adjuvant treatment for high-risk Hodgkin's disease in first complete remission after MOPP/ABVD protocol. Bone Marrow Transplant 1991; 8: 99–103
   PubMed Web of Science ®Google Scholar
• Gobbi P. G., Gobbi P. G., Mazza. P., Zinzani P.L. Multivariate analysis of Hodgkin's disease prognosis. Fitness and use of a directly predictive equation. Haematologica 1989; 74: 29–38
   PubMedGoogle Scholar
• Strauss D. J., Gaynor J. J., Myers J., Merke D. P., Caravelli J., Chapman D., Yahalom. J., Clarkson B.D. Prognostic factors among 185 adults with newly diagnosed advanced Hodgkin's disease treated with alternating potentially noncross-resistant chemotherapy and intermediate-dose radiation therapy. J Clin Oncol. 1990; 8: 1173–1186
   PubMed Web of Science ®Google Scholar
• Proctor S. J., Taylor P., Donnan P., Boys R, Lennard. A., Prescott. R. J. A numerical prognostlc index for clinical use in identification of poor-risk patients with Hodgkin's disease at diagnosis. Leukemia and Lymphoma. 1991; 7: 17–20
   Web of Science ®Google Scholar
• Kaplan. E. L., Meier. P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958; 53: 457–481
   Web of Science ®Google Scholar
• Peto. R., Peto. J. Asymptomatically efficient rank invariant test procedures. JR Stat Soc [A]. 1972; 135: 185–206
   Web of Science ®Google Scholar
• Dixon. D. J. Statistical software manual. University of California, Berkeley, CA 1990
   Google Scholar
• O'Brien M. E.R., Milan S., Jones A. L., Nicolson M., Selby P., Hickish T., Hill M., Gore. M. E., Winer. C. High dose chemotherapy and autologous bone marrow transplant in relapsed Hodgkin's disease - a pragmatic prognostic index. Brit J. Cancer 1996; 73: 1272–1277
   Web of Science ®Google Scholar
• Carde P., Mackintosh. F. R., Rosenberg. S. A. A dose and time response analysis in the treatment of Hodgkin's disease with MOPP chemotherapy. J. Clin Oncol. 1983; 1: 46–53
   Google Scholar
• Longo D. L., Young R. C., Wesley M., Hubbard S. M., Duffey P. L., Jaffe. ES. and Devita. V.T. Twenty years of MOPP therapy for Hodgkin's disease. J. Clin Oncol. 1986; 4: 1295–1306
   Google Scholar
• Pillai G. N., Hagemeister F. B., Velasquez W. S., Sullivan J. A., Johnston D. A., Butler. J. J., Shullenberger. C. C. Prognostic factors for stage IV Hodgkin's disease treated with MOPP, with or without Bleomycin. Cancer 1985; 55: 691–697
   PubMed Web of Science ®Google Scholar
• Specht. L., Nissan. N. I. Prognostic factors in Hodgkin's disease stage IV. Eur J Haematol. 1988; 41: 359–367
   PubMed Web of Science ®Google Scholar
• Fleury J., Legros M., Colombat P., Cure H., Travade P., Tortochaux J., Dionet C., Chollet P., Linassier C., Lamag-Nere J. P., Blaise D., Viens P., Maraninchi. D., Plagne. R. High-dose therapy and autologous bone marrow transplantation in first complete or partial remission for poor prognosis Hodgkin's disease. Leukemia and Lymphoma. 1995; 20: 259–266
   Web of Science ®Google Scholar
• Mauch P. M., Kalish L. A., Marcus K. C., Coleman C. N., Shulman L. N., Krill E., Come S., Silver B., Canellos. G. P., Tarbell. N. J. Second malignancies after treatment for laparotomy staged IA - IIIB Hodgkin's disease: long-term analysis of risk factors and outcome. Blood 1996; 87: 3625–3632
   PubMed Web of Science ®Google Scholar